| | | Needham & Company LLC reiterated their buy rating on shares of Geron ( NASDAQ:GERN – Free Report) in a research note released on Friday morning, Benzinga reports. Needham & Company LLC currently has a $6.00 price objective on the biopharmaceutical company’s stock.
Several other research analysts have also commented on the company. Barclays upgraded Geron to a “strong-buy” rating in a research report on Friday, November 29th. HC Wainwright reissued a “buy” rating and set a $9.00 target price on shares of Geron in a report on Tuesday, December 10th. Leerink Partners initiated coverage on shares of Geron in a report on Monday, September 9th. They issued an “outperform” rating and a $7.00 price target for the company. Leerink Partnrs raised shares of Geron to a “strong-buy” rating in a research report on Monday, September 9th. Finally, Scotiabank initiated coverage on shares of Geron in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $6.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $7.15.
Geron’s (GERN) Buy Rating Reiterated at Needham & Company LLC - Defense World |
|
